| Abstract | Genital human papilloma virus infection (HPV) is the most common sexually transmitted infection worldwide, it is the cause of genital warts, and it is related with cervical cancer, the second most common cause of death from cancer in women in America, and the first in underdeveloped countries, and it is related with penis and prostate cancer in males also, and with anal cancer in both genders. This review examines the most important actual facts about HPV infection, and the new prophylactic vaccines. Two versions of the vaccine had been developed, both target HPV 16 and HPV 18, which involve approximately 70% of cervical cancer. One of them also targets HPV 6 and HPV 11, which account for approximately 90% of external genital warts. Both vaccines have an excellent safety profile, are highly immunogenic, and have atributed complete type specific protection against persistent infection and associated lesions in fully vaccinated girls and young women. The role of men as carriers of HPV as well as vectors for transmission is well documented. Several clinical trials are currently under way to determine the efficacy of vaccinating men. Reducing the cost of vaccination would be a priority for the developing world in order to get a broad target in poor countries. |
| Authors | Alfredo César Juárez-Albarrán, Carlos Alberto Juárez-Gámez
(Affiliation: Hospital General de Zona 1, lnstituto Mexicano del Seguro Social (IMSS) Facultad de Medicina, Universidad de Colima, Colima, México. acja at hotmail.com)
|
| Journal | Revista médica del Instituto Mexicano del Seguro Social
(Rev Med Inst Mex Seguro Soc)
2008 Nov-Dec
Vol. 46
Issue 6
Pg. 631-7
ISSN: 0443-5117 [Print] Mexico |
| Vernacular Title | Vacuna contra el virus del papiloma humano. |
| PMID | 19263667
(Publication Type: English Abstract, Journal Article, Review)
|
| Chemical References |
|
| Topics |
- Female
- Humans
- Male
- Papillomavirus Infections
(prevention & control)
- Papillomavirus Vaccines
|
